EMBC

Attention Long-Term Shareholders of Embecta Corp. (NSADAQ: EMBC); Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); and ZoomInfo Technologies, Inc. (NASDAQ: GTM): Grabar Law Office is Investigating Claims on Your Behalf

Grabar Law Investigation Questions Embecta Governance and EMBC Shareholder Risk

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 &lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Grabar Law Office has opened a probe into Embecta&#039;s directors over fiduciary duties and governance, focusing on oversight, forecasting, and disclosures. The inquiry follows Embecta&#039;s weak May 2026 results and a sharp stock drop that underscored investor concern about governance practices. The catalyst could trigger reforms or legal costs, shifting EMBC&#039;s risk profile and valuation.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Grabar Law Office investigates Embecta for fiduciary-duty breaches.</li><li>Investigation focuses on oversight of operations, forecasting, and disclosures.</li><li>Embecta May 5, 2026 results missed expectations; FY2026 guidance reduced.</li><li>EMBC stock fell 57% in May 4-5, 2026 session.</li><li>Pre-Nov 25, 2025 holders may seek governance reforms at no cost.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Embecta Corp. (EMBC): Subject of fiduciary-duty probe; governance risk could affect stock.</li><li>Erasca, Inc. (ERAS): Also referenced in Grabar Law release; potential governance-related actions.</li><li>Hub Group, Inc. (HUBG): Part of broader governance-investigation coverage; market perception risk.</li><li>ZoomInfo Technologies, Inc. (GTM): Cited among companies facing similar shareholder-action scrutiny.</li></ul>
 </section>

 <section data-block="category">
 <h3>Legal</h3>
 Category: Legal. Fits due to shareholder governance investigations and potential actions like derivative suits; highlights investor activism risk and governance-related valuation concerns.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>Governance probe could drive near-term EMBC volatility.</li><li>May 2026 results miss and guidance cut set a weak baseline.</li><li>Pre-Nov 25, 2025 holders may pursue reforms at no cost.</li><li>Market will watch for updates on any governance resolutions.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Grabar Law investigating Embecta for fiduciary duties.</li><li>Date of article: July 10, 2026.</li><li>May 5, 2026: Q2 results below expectations; FY2026 guidance reduced.</li><li>Stock fell from $9.25 to $3.90 in May 4-5, 2026.</li><li>Holders since before Nov 25, 2025 eligible for claims.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Near-term EMBC price likely volatile; await governance-update clarity before trading.
 </section>
</section>


<article>
 <section>
 <h2>Grabar Law Office Investigates Embecta Corp. (EMBC) and Erasca, Inc. (ERAS) for Fiduciary Duty Violations</h2>
 PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) — Grabar Law Office has initiated investigations into the fiduciary duties of certain officers and directors of Embecta Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/EMBC">EMBC</a>) and Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ERAS">ERAS</a>). The inquiries focus on potential breaches related to corporate governance, oversight, disclosures, and internal controls.
 <ul>
 <li>EMBC stands for Embecta Corp., ticker EMBC, with investigations centered on fiduciary oversight and disclosures</li>
 <li>ERAS stands for Erasca, Inc., ticker ERAS, with investigations centered on governance and public statements</li>
 <li>The announcements were issued in connection with investor concerns raised by Grabar Law Office</li>
 </ul>
 </section>

 <section>
 <h3>Embecta Corp. Investigation Details (EMBC)</h3>
 WHAT IS THE INVESTIGATION ABOUT? Grabar Law Office is investigating allegations that Embecta's officers and directors failed to maintain appropriate oversight concerning the Company's business operations, sales performance, forecasting processes, internal controls, and public disclosures.
 If you have held Embecta Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/EMBC">EMBC</a>) shares since prior to November 25, 2025, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit <a href="https://www.globenewswire.com/Tracker?data=pbzDvO-5x_toDrDPbUdMgTWGQkY1mrbsF4nIVYATa6z2EGtWBHKaIhznzOVuKy9qRguy0acuRqnJTo7invHd96Qz0ORwjmib79OcdgAUcktlEZ-Rzy7fyNWDKiuFHq1ssimjhsvw_qje4PBWMAPX1fYRXxyGY4fiQWQdXqiKueEI2mXYYPS0UGHWE-Rxd5T1OFgd4U5WS6bFkEK-QlG5Jd12BGy7vLHvi_iFLlZrgeQ=" rel="nofollow" target="_blank">https://grabarlaw.com/the-latest/embecta-shareholder-investigation/</a>, contact Joshua H. Grabar at <a href="https://www.globenewswire.com/Tracker?data=Ssi7olqi5pqtMRE7VQvkH9u0JbLI5OAenodaa0SWU2Gvj50z14ChItvN5Mm4K-9GXP5-U33AZUlgLmcqGAqJpkfFOXtTW-Ryo6XG6MqauLQ=" rel="nofollow" target="_blank">jgrabar@grabarlaw.com</a>, or call us at 267-507-6085.
 WHY? According to a recently filed securities fraud class action complaint, Embecta Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/EMBC">EMBC</a>) repeatedly reaffirmed fiscal 2026 guidance and emphasized the stability and resilience of its pen needle business while allegedly failing to disclose adverse trends affecting that segment. On May 5, 2026, Embecta announced second quarter fiscal 2026 results that were significantly below prior expectations. The Company disclosed that revenue had declined substantially and reduced its fiscal year 2026 guidance. Embecta attributed the disappointing results primarily to weakness in its U.S. business, including share loss within its pen needle product category, softness in market volumes, pricing pressures, inventory reductions at certain accounts, and other adverse market dynamics. Following these disclosures, Embecta's stock price fell dramatically, declining from $9.25 per share on May 4, 2026 to $3.90 per share on May 5, 2026, representing a decline of more than 57% in a single trading session.
 WHAT CAN YOU DO NOW? If you are a current Embecta Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/EMBC">EMBC</a>) shareholder who has continuously held Embecta shares since before November 25, 2025, you are encouraged to visit <a href="https://www.globenewswire.com/Tracker?data=pbzDvO-5x_toDrDPbUdMgTWGQkY1mrbsF4nIVYATa6z2EGtWBHKaIhznzOVuKy9qRguy0acuRqnJTo7invHd9z8_RBFRrtAgL25bpepr33g5-17jgUcRfrNuggpQoULreJck3aR8EWuoQ_fkZe7oaa04HP7A_Qhjkpfv8FXLVT2E53c-2fgHxUt9VQaILGSHJa9As1MjgOEQK9gYII9By0l741OLKq6WmFcj4MyhWe0=" rel="nofollow" target="_blank">https://grabarlaw.com/the-latest/embecta-shareholder-investigation/</a>, contact Joshua H. Grabar at <a href="https://www.globenewswire.com/Tracker?data=Ssi7olqi5pqtMRE7VQvkH9u0JbLI5OAenodaa0SWU2HVNSkVC9Aoc4mQIxSnNoVDoMBV5qmu_owgjoY7HH_uyzZG3Ix1WeI1xQicSgx5zCs=" rel="nofollow" target="_blank">jgrabar@grabarlaw.com</a>, or call us at 267-507-6085. You can pursue claims on behalf of Embecta against officers and directors responsible for alleged misconduct and seek corporate governance reforms designed to improve oversight, accountability, and shareholder value as well as a court approved incentive award at no cost to them whatsoever. #EMBC $EMBC #Embecta
 </section>

 <section>
 <h3>Erasca, Inc. Investigation (ERAS)</h3>
 ERASCA, INC. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ERAS">ERAS</a>):
 Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ERAS">ERAS</a>) ("Erasca" or the "Company") breached their fiduciary duties owed to the Company and its shareholders.
 WHAT IS THE INVESTIGATION ABOUT? The investigation concerns whether Erasca's directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company's public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.
 If you are a current Erasca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ERAS">ERAS</a>) shareholder who has held shares since prior to January 14, 2025, you seek corporate governance reforms, damages on behalf of the Company, and other relief through a shareholder derivative action including a court approved incentive award at no cost to you whatsoever. Please visit
 <a href="https://www.globenewswire.com/Tracker?data=pbzDvO-5x_toDrDPbUdMgTWGQkY1mrbsF4nIVYATa6wtwQmOPHiAAqDTwhIvPhYf3wZU40Rwg2RJ6-Kc501LkRfnpbk_cXjtQxsbMcdANC2kS8mJdn_DsGw1H-e6pVjcVu0iHRva4Nm1xrMqYEMNxsBdpc3rP5iJ_F2vYUAemnqMqZrY70lYfKttxGBvSbA-QW1VjmxQURju648r6PoOng==" rel="nofollow" target="_blank">https://grabarlaw.com/the-latest/erasca-shareholder-investigation/</a>, contact Joshua H. Grabar at <a href="https://www.globenewswire.com/Tracker?data=Ssi7olqi5pqtMRE7VQvkH9u0JbLI5OAenodaa0SWU2HLmfJ-XIxm7sxMOuEw7nQEaxD28RgRXTxuPsXjqjM8jrNM0sxD6zOvL5NFg4a_Ib8=" rel="nofollow" target="_blank">jgrabar@grabarlaw.com</a>, or call us at 267-507-6085.
 WHY? According to a recently filed federal securities class action, investors allege that Erasca made materially misleading statements and omissions concerning ERAS-0015. Among other things, the complaint alleges that: Erasca publicly promoted ERAS-0015 as a potential "best-in-class" therapy and made repeated comparisons between ERAS-0015 and Revolution Medicines' RMC-6236; the Company's public disclosures allegedly relied upon improper comparisons to RMC-6236; Erasca allegedly faced intellectual property, patent, and trade-secret-related risks associated with those comparisons and related disclosures; investors allegedly were not adequately informed of those risks; and certain positive statements regarding ERAS-0015 allegedly lacked a reasonable basis.
 April 2026 Disclosures: On April 27, 2026, Erasca disclosed that it had received correspondence from counsel for Revolution Medicines alleging, among other things, patent infringement, trade-secret-related issues, and allegedly improper comparative statements concerning ERAS-0015 and RMC-6236. Later that same day, Erasca disclosed preliminary Phase 1 clinical data regarding ERAS-0015 and reported that one patient who received ERAS-0015 had died after experiencing pneumonitis that progressed following withdrawal of supportive care. The Company a...
 </section>
</article>

Grabar Law Office has opened a probe into Embecta's directors over fiduciary duties and governance, focusing on oversight, forecasting, and disclosures. The inquiry follows Embecta's weak May 2026 results and a sharp stock drop that underscored investor concern about governance practices. The catalyst could trigger reforms or legal costs, shifting EMBC's risk profile and valuation.

attention-long-term-shareholders-of-embecta-corp-nsadaq-embc-erasca-inc-nasdaq-eras-hub-group-inc-nasdaq-hubg-and-zoominfo-technologies-inc-nasdaq-gtm-grabar-law-office-is-investigating-claims-on-your-behalf

Attention Long-Term Shareholders of Embecta Corp. (NSADAQ: EMBC); Erasca, Inc. (NASDAQ: ERAS); Hub Group, Inc. (NASDAQ: HUBG); and ZoomInfo Technologies, Inc. (NASDAQ: GTM): Grabar Law Office is Investigating Claims on Your Behalf

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News